2024 Update: Novel Dyslipidemia Agents and Recommendations for Lowering LDL
by Lina M. Badwan, 2025 PharmD Candidate, Aaliyah Escamilla, 2025 PharmD Candidate, Shilpa Francis, 2025 PharmD/MPH Candidate, Parjot K. Kahlon, 2025 PharmD Candidate, Brianna J. Richards, 2025 PharmD Candidate
Abstract:
Dyslipidemia is a prevalent contributor to overall deaths in the United States. The 2018 American College of Cardiology/American Heart Association (ACC/AHA) guideline was published as a resource for healthcare providers and the general public to understand the treatment and management of dyslipidemia. In 2022, an ACC expert decision pathway focusing on the role of nonstatin therapies for low-density lipoprotein (LDL)-cholesterol lowering was published and explains dyslipidemia management strategies with nonstatin agents to prevent atherosclerotic cardiovascular disease (ASCVD). The expert decision pathway was designed to assess various factors of nonstatin therapy such as medication effectiveness, safety, and tolerability. Since this update, multiple new drugs have been developed to aid in the regulation of the disease. Inclisirian, bempedoic acid, evinacumab, and obicetrapib all differ in their functions but ultimately aim to reduce harm from dyslipidemia in affected individuals. This article aims to introduce recently approved medications that were not included in earlier clinical practice guidelines, highlighting the distinction between the existing guideline published in 2018 and the more recent 2022 ACC Expert Consensus Decision Pathway (ECDP) on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. In this review article, the authors will explore these new treatments and provide recommendations on their use in clinical practice, considering the updates laid out by the latest ECDP. This approach ensures a comprehensive understanding of how and when these newer options should be integrated into patient care.
Keywords: Dyslipidemia, low-density lipoprotein, cholesterol, atherosclerotic cardiovascular disease, HMG-CoA reductase
inhibitors, guideline review
Download PDF
2024 November/December Table of Contents
Abstract:
Dyslipidemia is a prevalent contributor to overall deaths in the United States. The 2018 American College of Cardiology/American Heart Association (ACC/AHA) guideline was published as a resource for healthcare providers and the general public to understand the treatment and management of dyslipidemia. In 2022, an ACC expert decision pathway focusing on the role of nonstatin therapies for low-density lipoprotein (LDL)-cholesterol lowering was published and explains dyslipidemia management strategies with nonstatin agents to prevent atherosclerotic cardiovascular disease (ASCVD). The expert decision pathway was designed to assess various factors of nonstatin therapy such as medication effectiveness, safety, and tolerability. Since this update, multiple new drugs have been developed to aid in the regulation of the disease. Inclisirian, bempedoic acid, evinacumab, and obicetrapib all differ in their functions but ultimately aim to reduce harm from dyslipidemia in affected individuals. This article aims to introduce recently approved medications that were not included in earlier clinical practice guidelines, highlighting the distinction between the existing guideline published in 2018 and the more recent 2022 ACC Expert Consensus Decision Pathway (ECDP) on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. In this review article, the authors will explore these new treatments and provide recommendations on their use in clinical practice, considering the updates laid out by the latest ECDP. This approach ensures a comprehensive understanding of how and when these newer options should be integrated into patient care.
Keywords: Dyslipidemia, low-density lipoprotein, cholesterol, atherosclerotic cardiovascular disease, HMG-CoA reductase
inhibitors, guideline review
Download PDF
2024 November/December Table of Contents